|1.||Bornmann, William G: 3 articles (05/2005 - 08/2004)|
|2.||Veach, Darren R: 3 articles (05/2005 - 08/2004)|
|3.||Clarkson, Bayard: 3 articles (05/2005 - 08/2004)|
|4.||Ilaria, Robert L: 1 article (05/2005)|
|5.||Wolff, Nicholas C: 1 article (05/2005)|
|6.||Tong, William P: 1 article (05/2005)|
|7.||Duyster, Justus: 1 article (02/2005)|
|8.||Aulitzky, Walter E: 1 article (02/2005)|
|9.||Sänger, Jana: 1 article (02/2005)|
|10.||van der Kuip, Heiko: 1 article (02/2005)|
|1.||Myeloproliferative Disorders (Myeloproliferative Disorder)
05/15/2005 - "In this study, we have used the murine CML-like myeloproliferative disorder as a platform to characterize the pharmacokinetic, signal transduction, and antileukemic properties of PD166326, one of the most potent members of the pyridopyrimidine class of protein tyrosine kinase inhibitors. "
02/15/2005 - "A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor."
05/15/2005 - "Consistent with its more potent antileukemic effect in vivo, PD166326 was also superior to imatinib mesylate in inhibiting the constitutive tyrosine phosphorylation of numerous leukemia-cell proteins, including the src family member Lyn. "
|3.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||Proteins (Proteins, Gene)